Home
About IBT
Vision and Mission
IBT History
Management
Board of Directors
Advisory Board
Sustainability Policy
Families
Healthcare Professionals
Science
Pipeline
IBP-9414
IBP-1016
Publications
Investors & Media
Shares
Presentations
Share Issue
Ownership Structure
Corporate Governance
Calendar
Financial Reports
Press Releases
News
Investors & Media Contact
Subscribe
Contact Us
Career
En
Sv
Home
About IBT
Vision and Mission
IBT History
Management
Board of Directors
Advisory Board
Sustainability Policy
Families
Healthcare Professionals
Science
Pipeline
IBP-9414
IBP-1016
Publications
Investors & Media
Shares
Presentations
Share Issue
Ownership Structure
Corporate Governance
Calendar
Financial Reports
Press Releases
News
Investors & Media Contact
Subscribe
Contact Us
Career
Press releases
Prospectus relating to IBT’s rights issue published
To access the press release, please read the following disclaimer
here
.
April 27, 2016
Latest press releases
Infant Bacterial Therapeutics AB (publ) (IBT), Interim Management Statement, July 1 – September 30, 2022
Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomination Committee for the Annual General Meeting 2023
Article based on Infant Bacterial Therapeutics’ (IBT) Connection Study published in the British Journal of Gastroenterology demonstrates that one day shift in Sustained Feeding Tolerance (SFT) correlates to clinically meaningful outcomes.
FDA approves Infant Bacterial Therapeutics’ request for a new orphan drug designation
Infant Bacterial Therapeutics AB (publ) Interim Management Statement January 1-June 30, 2022
This site uses cookies – small text-based files that are placed on your device to help us provide a better user experience.
Find out more.
Okay, thanks
